Envision Report

Published February 19, 2018

North America Insulin Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Request Free Sample Report!

Insulin is a hormone; a chemical messenger produced in one part of the body to have an action on another. It is a protein responsible for regulating blood glucose levels as part of metabolism. The body manufactures insulin in the pancreas, and the hormone is secreted by its beta cells, primarily in response to glucose. The beta cells of the pancreas are perfectly designed “fuel sensors” stimulated by glucose.

North America Insulin Market Segments Size & Growth:

North America Insulin Market size is projected to reach approximately $ XX billion by the end of 2024 with a CAGR of close to XX% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Growth in the Number of Diabetic Patients, Increasing Population Exposure to Key Risk Factors Leading to Diabetes, Rising Market Demand for HI Analogs, Technological Advancements in HI Delivery Devices, and Favourable Medical Reimbursement Scenario in Developed Countries. However, Stringent Regulatory Requirements for Product Approvalisthereby hampering the market growth.

North America Insulin Market Segments Share:

North America Insulin Market is categorised into product type which comprises drugs, and Delivery Devices. Among them, Drugs segment is expected to have largest market size during the forecast period because of its excess demand, rising proportion of the ageing population in developed countries, and Others. By Type, the market is segmented intoInsulin Analogs, Biosimilars, and Biologics. Among them, Biosimilars segment is expected to have largest market share during the forecast period because of its low-cost therapy. By Delivery Devices, the market is segmented into Syringes, Pens, and Pen Needles. Among them, Pens segment is expected to have largest market share during the forecast period because of the emerging markets. By Application, the market is segmented into Type I Diabetes, and Type II Diabetes. By Geography, USA holds the largest market share and is expected to maintain its dominant position during the forecast period. The changing lifestyle and lifestyle-related disorders are increasing the number of diabetic patients. High investments and involvement of more and more companies in research and development of insulin analogues and many ongoing clinical trials have created an environment for higher market growth shortly.

North America Insulin Market Trends:

  • Technologies are being explored to make the noninvasive delivery of insulin possible. Some of the routes of insulin administration that are under investigation are oral, buccal, nasal, peritoneal and transdermal.
  • BD launches the first syringe designed for use with Humulin R U-500 Insulin.

North America Insulin Market Research Report:                        

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

North America Diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial analysis with major competitors.

Expertise investment opportunities b an analyst to the individual and organisation to have a better foothold in the market.

The major market players, such as

  • NOVO Nordisk A/S
  • Eli Lilly and Company
  • Becton, Dickinson and Company
  • GlaxoSmithKline Plc
  • Merck & Co.

Chapter 1 Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of the Study

Chapter 2 Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

Chapter 3 Market Analysis

3.1 Industry Value Chain Analysis

3.2Porter’s Five Force Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threats

3.5 Y-O-Y Analyses

Chapter 4 Market Dynamics

4.1. Drivers

4.1.1 Growth in the Number of Diabetic Patients

4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes

4.1.3 Rising Market Demand for HI Analogs

4.1.4 Technological Advancements in HI Delivery Devices

4.1.5 Favourable Medical Reimbursement Scenario in Developed Countries

4.2 Restraints

4.2.1 Stringent Regulatory Requirements for Product Approval

4.3 Opportunities

4.3.1 Expected Patent Expiry of Key HI Drugs

4.3.2 Emerging Markets

4.4 Challenges

4.4.1 High Product Manufacturing Costs

Chapter 5 North America Insulin Market– By Product Type

5.1 Drugs

5.2 Delivery Devices

Chapter 6 North America Insulin Market– By Type

6.1 Insulin Analogs

6.2 Biosimilars

6.3 Biologics

Chapter 7 North America Insulin Market- By Delivery Devices

7.1 Syringes

7.2 Pens

7.3 Pen Needles

Chapter 8 North America Insulin Market- By Application

8.1 Type I Diabetes

8.2 Type II Diabetes

Chapter 9 North America Insulin Market- By Geography

9.1 Introduction

9.2 U.S.

9.3 Canada

9.4 Mexico

Chapter 10 North America Insulin Market- Company Profiles

10.1B. Braun Melsungen AG

10.1.1. Company Overview

10.1.2. Business Segments

10.1.3. Financial Performance ( Public Enterprises)

10.1.4. SWOT Analysis

10.2 Biocon Limited

10.3 Becton, Dickinson and Company

10.4 Eli Lilly and Company

10.5 Biodel Inc.

10.6 Julphar

10.7 NOVO Nordisk A/S

10.8 Sanofi

10.9 Wockhardt Limited

10.10 Ypsomed AG

10.11 Oramed Pharmaceuticals Inc.

10.12 Dongbao Enterprises Group Co. Ltd.

10.13 Merck & Co.

10.14 GlaxoSmithKline Plc

Chapter 10 North America Insulin Market- Competitive Landscape

10.1. Market Share Analysis

10.2Strategies Adopted by top companies

10.3. Mergers, Acquisitions, Collaborations & Agreements

Chapter 11 Market Insights

11.1. Industry Experts Insights

11.2. Analysts Opinions

11.3. Investment Opportunities

Chapter 12 Appendix

12.1 List of Tables

12.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.

 

©2018 - Envision Inteligence | All Rights Reserved.